$992 Million is the total value of Vivo Capital, LLC's 44 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ASND | Ascendis Pharmaadr | $153,542,000 | +6.5% | 2,166,832 | 0.0% | 15.48% | -16.7% | |
| BHVN | Biohaven Pharmaceutical Holding Company Ltd | $76,960,000 | -5.0% | 2,049,545 | 0.0% | 7.76% | -25.7% | |
| MNLO | Menlo Therapeutics | $39,511,000 | +21.3% | 4,011,236 | 0.0% | 3.98% | -5.1% | |
| KDMN | Kadmon Holdings (KDMN) | $34,918,000 | -49.3% | 10,454,545 | 0.0% | 3.52% | -60.4% | |
| TCDA | Tricida, Inc. | $30,297,000 | +2.2% | 991,711 | 0.0% | 3.05% | -20.1% | |
| ACRS | Aclaris Therapeutics | $23,918,000 | -27.3% | 1,647,214 | 0.0% | 2.41% | -43.1% | |
| EIGR | Eiger BioPharmaceuticals | $21,495,000 | -1.6% | 1,791,257 | 0.0% | 2.17% | -23.1% | |
| VRNA | Verona Pharma Plcads | $18,677,000 | +568.9% | 1,492,951 | 0.0% | 1.88% | +422.8% | |
| KALA | Kala Pharmaceuticals, Inc. | $10,295,000 | -28.1% | 1,043,020 | 0.0% | 1.04% | -43.7% | |
| CBAY | Cymabay Therapeutics inc | $10,038,000 | -17.4% | 906,000 | 0.0% | 1.01% | -35.4% | |
| ZYME | Zymeworks Inc | $9,736,000 | +6.2% | 620,134 | 0.0% | 0.98% | -16.9% | |
| SLNO | Soleno Therapeutics, Inc. | $9,417,000 | -7.7% | 4,359,683 | 0.0% | 0.95% | -27.8% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $8,056,000 | +17.9% | 1,213,290 | 0.0% | 0.81% | -7.7% | |
| GNCA | Genocea Biosciences Inc(NMS) | $6,378,000 | -8.9% | 8,180,000 | 0.0% | 0.64% | -28.7% | |
| ZGNX | Zogenix, Inc. | $5,208,000 | +12.2% | 105,000 | 0.0% | 0.52% | -12.2% | |
| ZLAB | Zai Lab LTDadr | $4,500,000 | -16.2% | 231,010 | 0.0% | 0.45% | -34.4% | |
| SRRA | Sierra Oncology, Inc | $4,145,000 | -42.6% | 2,438,270 | 0.0% | 0.42% | -55.1% | |
| TRVN | Trevena, Inc. | $3,663,000 | +47.2% | 1,728,000 | 0.0% | 0.37% | +15.0% | |
| BPMX | BioPharmX Corporation | $3,064,000 | -14.0% | 16,128,515 | 0.0% | 0.31% | -32.7% | |
| AKTX | Akari Therapeutics Plcadr | $885,000 | +31.3% | 345,850 | 0.0% | 0.09% | +2.3% | |
| AGRX | Agile Therapeutics, Inc. | $555,000 | -25.2% | 1,513,975 | 0.0% | 0.06% | -41.7% | |
| SNSS | Sunesis Pharmaceuticals, Inc. | $391,000 | -5.6% | 195,474 | 0.0% | 0.04% | -26.4% | |
| SLNOW | Soleno Therapeutics, Inc.warrant | $23,000 | -70.9% | 188,772 | 0.0% | 0.00% | -80.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
| CODEXIS INC | 29 | Q3 2023 | 8.0% |
| ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
| KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
| Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
| AMYRIS INC | 23 | Q3 2023 | 8.8% |
| EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
| Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
| Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
| HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-22 |
| 13F-HR | 2024-02-07 |
| 13F-HR | 2023-11-08 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.